National Guideline Clearinghouse | American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

full-text ►

National Guideline Clearinghouse | American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.



American Gastroenterological Association Institute

Guideline Title

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Bibliographic Source(s)

Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015 Jan;148(1):215-9. [4 references] PubMed

Guideline Status

This is the current release of the guideline.

This guideline meets NGC's 2013 (revised) inclusion criteria.

.-.-.



American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppres... - PubMed - NCBI

Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7. doi: 10.1053/j.gastro.2014.10.039. Epub 2014 Oct 31.

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Reddy KR1, Beavers KL2, Hammond SP3, Lim JK4, Falck-Ytter YT5; American Gastroenterological Association Institute.

Collaborators (13)

Author information

Erratum in

• Gastroenterology. 2015 Feb;148(2):455. multiple investigator names added.

PMID:

 

25447850

 

[PubMed - indexed for MEDLINE]